Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03
(2025) Journal of Thoracic Oncology — (2025)
Files
101016-jjtho202412028_doc.pdf
Open Access - Adobe PDF
- 611.45 KB
Details
- Authors
Dowlati, Afshin 
- Abstract
- Introduction: The phase 2 TROPiCS-03 study evaluated the efficacy/safety of sacituzumab govitecan (SG) as second-line treatment in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). Methods: TROPiCS-03 (NCT03964727) is a multicohort, open-label, phase 2 basket study in solid tumors, including ES-SCLC. Adults with ES-SCLC that progressed after one prior line of platinum-based chemotherapy and anti-programmed death-(ligand) 1 (PD-[L]1) therapy received SG 10 mg/kg on days 1 and 8 of a 21-day cycle. The primary endpoint was investigator-assessed objective response rate (ORR), per RECIST v1.1. Key secondary endpoints included investigator-assessed duration of response (DOR) and progression-free survival (PFS); blinded independent central review (BICR)-assessed ORR, DOR, and PFS; overall survival (OS); and safety. Efficacy was evaluated in patients with platinum-resistant and platinum-sensitive disease. Results: Among 43 patients (median follow-up, 12.3 [range, 8.1-20.1] months), investigator-assessed ORR was 41.9% (95% CI: 27.0%-57.9%), with 18 confirmed partial responses; median (95% CI) DOR, PFS, and OS were 4.73 (3.52-6.70), 4.40 (3.81-6.11), and 13.60 (6.57-14.78) months, respectively. Efficacy results by BICR assessment were similar. Investigator-assessed ORR (95% CI) was 35.0% (15.4%-59.2%) in patients with platinum-resistant disease (n=20) and 47.8% (26.8%-69.4%) with platinum-sensitive disease (n=23). Thirty-two (74.4%) patients experienced grade ≥3 treatment-emergent adverse events (TEAEs). No TEAE led to SG discontinuation; one treatment-related TEAE (neutropenic sepsis) led to death. Conclusions: SG demonstrated promising efficacy in the second-line treatment of ES-SCLC, irrespective of platinum sensitivity. Safety was manageable and consistent with that observed in other SG studies.
- Affiliations
Citations
Dowlati, A., Chiang, A. C., Cervantes, A., Babu, S., Hamilton, E., Wong, S. F., Tazbirkova, A., Sullivan, I. G., van Marcke de Lummen, C. J., Italiano, A., Patel, J., Mekan, S., Wu, T., & Waqar, S. N. (2025). Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From TROPiCS-03. Journal of Thoracic Oncology. Published. https://doi.org/10.1016/j.jtho.2024.12.028 (Original work published 2025)